CANAssess 2: managing cancer patients’ needs in GP Surgeries through the use of a Needs Assessment Tool (NAT-C)

Not Applicable

Completed

• Conditions: eoplasms of uncertain or unknown behaviour; Cancer; Neoplasms of uncertain or unknown behaviour

• Registration Number: ISRCTN15497400
• Lead Sponsor: niversity of Hull

Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35508352/ (added 05/05/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-07
• Study Completion: 2024-01-19
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 788

Inclusion Criteria

GENERAL PRACTICES:
1. Willing to be trained and to offer and use the NAT-C, if so allocated, for all recruited patients
2. Willing to commit to trial procedures:
2.1. Supporting screening and inviting patients to participate
2.2. Allowing researchers access to the GP surgery to support the study
3. Capacity to recruit approximately 20 patients
4. Written informed consent provided by practice manager or deputy

PATIENTS:
1. Adults (aged 18 years and above)
2. Diagnosis of active cancer (receiving anti-cancer treatment both with curative or palliative intent; managed with watch and wait”; recurrent or metastatic; or inoperable) Note: anti-cancer treatment includes any treatment designed to modify the growth of the cancer, such as chemotherapy, immunotherapy, hormone therapy, radiotherapy, or surgery
3. Willing and able to complete questionnaires at the trial follow-up schedule (able to complete trial measures
4. Provision of written or observed verbal informed consent.
5. Sufficient knowledge of the English language to provide informed consent and complete trial questionnaires. The use of an appropriate translator/interpreter is allowed

CARERS:
1. Adults (aged 18 years and above)
2. Nominated by the patient
3. Able to complete trial measures
4. Written or observed verbal informed consent
5. Sufficient knowledge of the English language to provide informed consent and complete trial questionnaires. The use of an appropriate translator/interpreter is allowed

PROCESS EVALUATION - CLINICIANS:
1. Any clinician who has received NAT-C training (survey 1)
2. Any clinician who has delivered the NAT-C intervention (survey 2)
3. Any clinician who has received NAT-C training and/or delivered the NAT-C intervention (interview)

PROCESS EVALUATION - OTHER GP STAFF:
1. Practice management and administrative staff in participating intervention practices

PROCESS EVALUATION - KEY STAKEHOLDERS:
1. Identified by the research team or clinical experts as having a key role in health policy and commissioning, relevant to cancer care in primary care

Exclusion Criteria

Current exclusion criteria as of 01/03/2022:
GP surgeries that do not meet the inclusion criteria will be excluded

PATIENTS:
1. In complete remission (no clinical or radiological evidence of cancer, and at least one-month post anti-cancer treatments)
2. With basal cell carcinoma only
3. Living in a care home or other institutional setting
4. Within 1 month of receiving their initial cancer diagnosis

CARERS:
1. Employed to look after the patient

PROCESS EVALUATION - CLINICIANS:
1. Clinicians on the Usual Care arm of the study

PROCESS EVALUATION - OTHER GP STAFF:
1. Practice management and administrative staff on the Usual Care arm of the study

Previous exclusion criteria:
GENERAL PRACTICES:
1. Locum GPs who work across general practices and registrars due to leave the practice before the end of the trial will be excluded to avoid potential contamination
2. GP surgeries with existing or planned (within the recruitment period of the trial) systematic implementation of cancer care review services/holistic needs assessments, which have the potential to significantly overlap with the NAT-C (as determined by the CI & GP hub leads), will be excluded.

PATIENTS:
1. In complete remission (no clinical or radiological evidence of cancer, and at least 1-month post anti-cancer treatments)
2. With basal cell carcinoma
3. Living in a care home or other institutional setting
4. Within 1 month of receiving their initial cancer diagnosis

CARERS:
1. Paid carers

PROCESS EVALUATION - CLINICIANS:
1. Clinicians on the Usual Care arm of the study

PROCESS EVALUATION - OTHER GP STAFF:
1. Practice management and administrative staff on the Usual Care arm of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified